START Hope Hub Connect Patients and Physicians with Faster, Smarter Trial Access

ARANOTE Trial: Darolutamide Shows Significant Quality-of-Life Improvements in mCS Prostate Cancer

ATOMIC Trial: Atezolizumab Combo Halves Recurrence in Stage III dMMR Colon Cancer

Targeted ADC ZL-1310 Shows Promising 67% ORR in Heavily Pretreated ES-SC Lung Cancer

Darzalex Faspro Achieves Outstanding Results in Multiple Myeloma with 95% 4-Year PFS

AI-Driven bioX Genetics Platform Slashes Genetic Variant Detection Time

Vividion and Bayer Advance First-in-Class WRN Inhibitor VVD-214 for Solid Tumors

IMforte Study: Tecentriq Plus Lurbinectedin Extends Survival in ES-SC Lung Cancer

OASIS-4 Trial: Elinzanetant Reduces Hot Flashes in Breast Cancer Treatment

BioNTech and BMS Forge Partnership to Advance BNT327 for Solid Tumors

Pasritamig’s Favorable Safety and Efficacy in Advanced Prostate Cancer

Imdelltra Extends Survival in Small Cell Lung Cancer, Cutting Death Risk by 40%

Libtayo Demonstrates 68% Risk Reduction in High-Risk CS Cell Carcinoma

Inavolisib Combination Doubles PFS in PIK3CA Mutated Advanced Breast Cancer

The Latest Issue of ONCOLife Is Now Live – Follow the Cutting Edge of Oncology Innovation

START and OneOncology Partnership Expands Clinical Trials from Academia to Community

DNA-Based Immunotherapy IMNN-001 Shows Survival Gains in Advanced Ovarian Cancer

MB-105 CAR-T Therapy: Advancing Precision Treatment for CD5+ T-Cell Lymphoma

EU Commission Approves Opdivo Regimen for High-Risk Resectable NSCLC

FDA Approves First Blood Test for Alzheimer’s, Marking a Historic Shift in Early Detection

START Doses First Patient in Trial of mRNA-4106, a Pan-Tumor Therapy for Solid Tumors

FDA Approves Emrelis as the First Targeted ADC for High c-Met Expressing Lung Cancer

ONCOLife Warmly Welcomes Dr İlkiz Er Dağ as ONCOLife Project Director

V Foundation and Cancer Vaccine Coalition Partner to Accelerate Breast Cancer Vaccine

10-Year Results Confirm Pertuzumab Combo Extends Survival in HER2+ Breast Cancer

Adcentrx’s Nectin-4 ADC, ADRX-0706, Earns FDA Fast Track for Cervical Cancer

Bria-IMT’s Early Promise: Biomarkers Signal Path to Personalized Therapy in Breast Cancer

Leucid Bio Doses First Patient in Trial of LEU011, a CAR-T Therapy for Solid Tumors

Zongertinib Demonstrates 71% Response Rate in HER2-Mutant Lung Cancer Treatment

Elraglusib Shows Survival Benefit in First-Line Metastatic Pancreatic Cancer Trial

First-Ever KRAS G12D Inhibitor Zoldonrasib Shows 61% Response Rate in Lung Cancer

Durvalumab Plus BCG Boosts Outcomes in Early-Stage Bladder Cancer

Avutometinib Earn Accelerated FDA Approval for Ovarian Cancer

FDA Announces AI Strategy with First AI-Assisted Scientific Pilot for Drug Review

Enhertu Outperforms Chemotherapy in Early-Stage HER2+ Breast Cancer

Combined Tissue and Liquid Biopsies Improve Survival in Advanced Solid Tumors

First AI-Driven Diagnostic Tool Wins FDA Breakthrough Designation for Lung Cancer

Pembrolizumab Improves Event-Free Survival in Resectable Head and Neck Cancer

Bayer Launches First-in-Human Trial of Targeted Alpha Therapy for Advanced Liver Cancer

Merck Expands US Bio Manufacturing with $1B Wilmington Facility for KEYTRUDA

Gut Bacteria as Co-Therapy: MB097’s Role in Overcoming Resistance in Melanoma

Sasanlimab Plus BCG Shows Significant Survival Benefit for NMI Bladder Cancer

New Hope for SPG47: BlackfinBio’s BFB-101 Gene Therapy Advances with FDA Approval

Enhertu Redefines First-Line Treatment for HER2+ Metastatic Breast Cancer

Trodelvy and Keytruda Combination Marks Breakthrough in mTN-Breast Cancer

Ivonescimab Shows Significant Improvement in First-Line Treatment of NSCLC

Nimbus Launches First Human Trial of Promising WRN Inhibitor for MSI-H Cancers

SkinJect Patch Shows Early Success in Phase 2 Study for Basal Cell Carcinoma

First Patient Dosed in Phase 2 Trial of MB-105, CD5 CAR-T Therapy for T-Cell Lymphoma

Boehringer and Tessellate Partner to Develop Treatments for Hard-to-Treat Cancers